Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Propanc Biopharma, Inc.

Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces Reverse Stock Split
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Offers a Novel Way to Stop Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.